缓慢乙型肝炎抗病毒医治专家一致 2012年APASL亚太一致声明：缓慢乙型肝炎的医治

Since the 4th version of the "Asian-Pacific consensus statement on the management of chronic hepatitis B" was published in September 2008, tenofovir has been approved globally and several updated  guidelines on chronic hepatitis B virus (HBV) infection have been published. Large amounts of new data on the natural history and treatment of chronic HBV infection have also become available or are emerging. These include further studies in asymptomatic subjects with chronic HBV infection and community-based cohorts, the role of HBV genotype and naturally occurring HBV mutations, the application of non-invasive methods in the assessment of hepatic fibrosis, the clinical utility of quantitative hepatitis B surface antigen (HBsAg), and newer drugs or new strategies towards more effective management. We have closely followed the progress in the field and invited experts from the Asian-Pacific region to review and assess relevant new data. The significance of the reported findings was discussed and debated during an expert meeting in Taipei, Taiwan on October 22–23, 2011. The 2008 update of the "Asian-Pacific consensus statement on the management of chronic hepatitis B" was revised accordingly. The key terms defined in the 2008 statement were also revised (Table 1). Then, the revised version was circulated for further comments, and it was refined through electronic communications among the experts. The revised contents were presented and discussed at the Asian-Pacific Association for the Study of the Liver meeting in Taipei, Taiwan in February 2012. The following is the final version of the updated consensus and recommendations on the management of chronic hepatitis B.